The MOA of LL is completely dissociated from the specific strain of COVID. LL directly (and specifically) targets lymphocytes expressing CCR5 (T cells, monocytes). Normally CCR5 would cause lymphocyte homing to sites of inflammation, as CCR5 lymphocytes would migrate towards chemokines such as CCL3 and CCL4. LL blockade of CCR5 prevents this migration and acts to break the positive feedback cycle of inflammation that ultimately culminates in a cytokines storm.

Since LL targets lymphocytes directly there is a much broader therapeutic landscape than just COVID.